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Meta-Immunological Profiling of Children With Type 1
Diabetes Identifies New Biomarkers to Monitor
Disease Progression
Mario Galgani,1,2 Rosa Nugnes,1 Dario Bruzzese,3 Francesco Perna,4 Veronica De Rosa,1,2,5
Claudio Procaccini,1,2 Enza Mozzillo,6 Corrado M. Cilio,7 Helena Elding Larsson,7 Åke Lernmark,7
Antonio La Cava,8 Adriana Franzese,6 and Giuseppe Matarese1,2
Type 1 diabetes is characterized by autoimmune destruction of
pancreatic b-cells in genetically susceptible individuals. Triggers
of islet autoimmunity, time course, and the precise mechanisms
responsible for the progressive b-cell failure are not completely
understood. The recent escalation of obesity in affluent countries
has been suggested to contribute to the increased incidence of
type 1 diabetes. Understanding the link between metabolism and
immune tolerance could lead to the identification of new markers
for the monitoring of disease onset and progression. We studied
several immune cell subsets and factors with high metabolic im-
pact as markers associated with disease progression in high-risk
subjects and type 1 diabetic patients at onset and at 12 and 24
months after diagnosis. A multiple correlation matrix among dif-
ferent parameters was evaluated statistically and assessed visu-
ally on two-dimensional graphs. Markers to predict residual b-cell
function up to 1 year after diagnosis were identified in multivar-
iate logistic regression models. The meta-immunological profile
changed significantly over time in patients, and a specific signa-
ture that was associated with worsening disease was identified. A
multivariate logistic regression model measuring age, BMI, fast-
ing C-peptide, number of circulating CD3+CD16+CD56+ cells, and
the percentage of CD1c+CD192CD142CD3032 type 1 myeloid
dendritic cells at disease onset had a significant predictive value.
The identification of a specific meta-immunological profile asso-
ciated with disease status may contribute to our understanding of
the basis of diabetes progression. Diabetes 62:2481–2491, 2013
Type 1 diabetes is an autoimmune disease char-acterized by T cell–mediated destruction of insulin-secreting pancreatic b-cells in genetically susceptibleindividuals (1). The clinical onset is commonly
preceded by a prodromal period characterized by sero-
conversion to islet autoantibody positivity and by sub-
tle metabolic disturbances. The development of type 1
diabetes involves a complex interaction between pancre-
atic b-cells and both arms of the innate and adaptive im-
mune system, which undoubtedly changes during the
progression of the disease (1). Altered functions, an im-
balance of immune cell subsets, or both, and metabolic/
inflammatory molecules may contribute to the initiation
and progression of the b-cell autoimmune responses
resulting in the clinical onset of the disease (1).
In the past decades, we have witnessed a dramatic
obesity epidemic from Western affluent countries into the
developing world. It has been estimated that there are 1.5
billion overweight individuals worldwide, of which ;500
million are frankly obese (1,2). This rising trend has been
paralleled by a similarly dramatic increase in the incidence
of type 1 diabetes, which has doubled in the past 15 years.
This increased incidence appears not to be uniformly dis-
tributed: type 1 diabetes associated with high risk HLA
alleles has remained stable, whereas that associated with
low-risk genotypes has increased significantly and has
shown a tendency to associate with obesity and insulin
resistance (3). Indeed, cohort studies have shown that
children who developed type 1 diabetes are heavier in the
first year of life compared with their peers who remain free
of disease and that an increasing BMI strongly correlates
with an earlier disease presentation (4–6). Also, insulin-
resistance related to overweight not only often preceded
clinical onset but was also the strongest predictor of type 1
diabetes, aside from HLA genotype (7,8).
The study of the pathogenesis of early type 1 diabetes in
humans requires long follow-up of a large number of
subjects, of which only a small fraction will progress to
overt disease, due to the relatively low incidence of this
disease in the general population and also among subjects
at genetic risk.
Meta-immunology has been developing during the last
10 years and can be used in the study of type 1 diabetes to
link metabolism with immunity, including immune tol-
erance. Most of the studies that have examined meta-
immunologic parameters in type 1 diabetes have had
discrepant results and did not yield definitive conclusions
(9–12). Moreover, they typically involved relatively small
numbers of subjects and analyzed single (or a few)
parameters (12). More important, no study so far has ex-
amined meta-immunologic parameters for the prediction
of residual b-cell function over time (e.g., via the moni-
toring of metabolic and immunologic functions charac-
terizing type 1 diabetes).
Here we compared the meta-immunologic profiles of
high-risk children, children with newly diagnosed type 1
diabetes, and control subjects. The analysis of 2 years of
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follow-up of meta-immunologic markers correlated with
multiple parameters at disease onset and over time. A
simple decision rule model based on a multivariate logistic
regression analysis capable of predicting at diagnosis was
developed, providing a way for discriminating, at diagnosis,
children who will maintain good b-cell function from those
who will lose their function up to 1 year from diagnosis.
RESEARCH DESIGN AND METHODS
Subjects. Children (n = 114, Supplementary Table 1) who received the di-
agnosis of type 1 diabetes were recruited after glycemic stabilization on ex-
ogenous insulin, achieved in 5 days. Diabetes was defined according to the
Global International Diabetes Federation/International Society for Pediatric
and Adolescent Diabetes Guidelines for Diabetes in Childhood and Adoles-
cence and included symptoms of diabetes in addition to casual plasma glucose
concentration $11.1 mmol/L (200 mg/dL), or fasting plasma glucose $7.0
mmol/L ($126 mg/dL), or 2 h postload glucose $11.1 mmol/L ($200 mg/dL)
during an oral glucose tolerance test, and glycated hemoglobin (HbA1c) $6.5
(13). Among the 114 diabetic children, 40 had ketoacidosis at disease on-
set, and 25 had at least another autoimmune disorder besides autoimmune
diabetes—more frequently celiac disease (n = 12) or autoimmune thyroiditis
(n = 13). The following criteria were used to select 34 healthy control subjects
(Table 1): fasting blood glucose of ,5.5 mmol/L (,100 mg/dL), negative per-
sonal and familial history of autoimmune disorders, and negativity for islet
autoantibodies at the 99th percentile. The diabetic children and control sub-
jects were recruited in the Department of Pediatrics at the University of
Naples Federico II. A local ethical committee approved the study, and parents
gave informed consent.
The third group, designed as high-risk subjects, included 29 individuals
recruited from baseline of the Diabetes Prevention–Immune Tolerance study at
the Skåne University Hospital, Malmö, Sweden. Children carrying HLA sus-
ceptibility alleles for type 1 diabetes were defined as high-risk based on the
presence of GAD65 autoantibodies (GADA) and at least one more islets-
specific autoantibodies (IA-2 antigen, zinc transporter type 8 autoantibodies,
or insulin autoantibody). The Lund Regional Ethics Board approved the study,
and informed consent was obtained from all subjects or their parents in ac-
cordance to the Declaration of Helsinki. There was no significant difference
among the three study groups concerning sex and BMI standard deviation
score (14). High-risk subjects were younger and consequently had lower BMIs
than control subjects and patients with diabetes at onset. Characteristics of
the study subjects are summarized in Supplementary Table 1.
Study design. At the beginning of the study, children from each group were
analyzed for a wide range of immune (Supplementary Table 2) and metabolic
parameters (Supplementary Table 3). Diabetic children were monitored for 12
(n = 60) to 24 (n = 30) months after disease onset and were then analyzed for
the same parameters measured at the diagnosis. In addition, patients were
dichotomized into two groups on the basis of residual fasting C-peptide
(C-pep) evaluated 1 year after disease diagnosis. Specifically, diabetic children
with C-pep ,0.5 ng/mL were designed as “severe-disease patients,” whereas
patients with C-pep levels .0.5 ng/mL were defined “mild-disease patients.”
A multivariate logistic regression analysis was performed to identify, at the
time of diagnosis, biological parameters predictive of a maintained pancreatic
function 12 months later. To exclude the possible influence of glucose levels on
metabolic parameters, blood was drawn when glycemic values were in the
range of 80–180 mg/dL (4.4–10 mmol/L). The actual glucose levels at time of
draw were not considered in the analysis.
Flow cytometry. Immune cell profiling of cells from the subjects of the three
groups was done at the time of the blood draw. Before flow cytometry to
determine lymphocyte subsets, whole blood cells were analyzed with a clinical-
grade hematocytometer to determine absolute lymphocyte numbers in each
sample. For the control subjects and type 1 diabetes patients, 100 mL blood was
incubated 30 min at room temperature with the specific antibodies combina-
tions. Erythrocytes were lysed using BD FACS lysing Solution 2 (BD Bio-
science) for 10 min and samples subsequently washed and resuspended in 300
mL PBS. Flow cytometry was carried out on cells gated on CD45+ - Side
Scatter (SSC). Immunophenotypic analysis was performed with an EPICS XL
flow cytometer (Beckman Coulter, Milan, Italy) using the Beckman Coulter XL
System II software program. Triple combinations of different human mono-
clonal antibodies (e.g., fluorescein isothiocyanate [FITC]– and phycoerythrin
[PE]–anti-CD3, PE– and PC-5–anti-CD4, PC5–anti-CD8, PE–anti-CD16, PC5–
anti-CD19, PE–anti-CD25, FITC–anti-CD45, and PE–anti-CD56; all from Coul-
ter Immunotech, Marseille, France) were used to identify different cell
populations. For high-risk subjects, whole-blood samples were stained with
the following monoclonal anti-human antibodies in various combinations for
flow cytometry: FITC-conjugated CD3; PE-conjugated CD19 and CD8; peri-
dinin chlorophyll protein (PerCP)-conjugated CD4; CD16 and CD56 (PE; all
from BD Bioscience, Becton, Dickinson, Franklin Lakes, NJ). Briefly, 100 mL
blood was used for each staining, and samples were incubated 20–30 min at
room temperature. Erythrocytes were lysed using BD FACS lysing Solution 2,
and samples were washed and resuspended in 300 mL fluorescence-activated
cell sorter buffer for flow cytometry. Lymphocytes cell analysis was done on
gated CD45+ SSC cells with a FACSCalibur (BD Bioscience, Franklin Lakes,
NJ). Data were analyzed using CellQuest software (Becton Dickinson). No dif-
ferences in the analysis of three studied groups can be ascribed to the pro-
cedures used because the same clones of monoclonal antibodies and similar
experimental conditions were used in the flow cytometry setting.
Circulating myeloid (mDCs) and plasmacytoid (pDCs) dendritic cells were
evaluated using the Blood Dendritic Cells Enumeration Kit (Miltenyi Biotec,
Germany). Specifically, mDC1s, mDC2s, and pDCs were identified based on the
expression of CD1c, CD141, and CD303 markers, after exclusion in the analysis
of the CD19+ and CD14+ cells, respectively. The samples were analyzed by
a CyAn flow cytometer and Summit software (Instrumentation Laboratory,
Bedford, MA). Cell numbers are expressed as the percentage of a given cell
population multiplied by number of lymphocytes/100, except for the number
of DCs, for which the percentage was referred to white blood cells (WBCs).
Laboratory tests. For control subjects and high-risk subjects, a 4-mL blood
samplewas obtained at the time of recruitment. For patients, a 4-mL blood sample
was obtained at diabetes onset, after 12months, and at 24months. An aliquot from
each blood sample was used to perform immune cell profiling by flow cytometry,
and the remaining part of the sample was used for serum-based assays. Sera were
centrifuged and kept at –80°C until use. Fasting C-pep levels were measured in
duplicate serum samples, at the same time in all samples, using a commercial
ELISA kit (Millipore Corporation, Billerica, MA). Results for each assay were
validated, and a high-level and a low-level control sample were included.
Circulating leptin (Lep) and soluble leptin receptor (sLepR) were de-
termined in duplicate serum samples using human Leptin and human Leptin sR
Immunoassays, respectively (R&D Systems Inc., Minneapolis, MN).
Soluble CD40 L (sCD40 L), soluble intracellular adhesionmolecule (sICAM-1),
monocyte chemoattractant protein-1 (MCP-1), myeloperoxidase (MPO), osteo-
protegerin (OPG), resistin, and soluble tumor necrosis factor receptor (sTNFR)
were analyzed using the bead-based analyte detection system Human Obesity
9plex kit (Bender MedSystem Inc, Burlingame, CA) in duplicate serum samples.
Plasma glucose levels were measured using enzymatic hexokinase method.
HbA1c was measured by high-performance liquid chromatography (HLC-723
TABLE 1
Estimated regression coefficients and adjusted odds ratio (95% CI) for predictors of residual C-pep secretion in the base and in the full
logistic regression model
Base model Full model
Estimated
coefficient OR (95% CI) P
Estimated
coefficient OR (95% CI) P
Age at diagnosis 20.175 0.84 (0.69–1.03) 0.091 20.376 0.69 (0.51–0.93) 0.015
BMI at diagnosis 0.064 1.07 (0.92–1.24) 0.406 0.119 1.13 (0.92–1.39) 0.262
C-pep secretion at diagnosis
#0.5 ng/mL 2.259 9.57 (1.83–50.11) 0.008 2.390 10.91 (1.81–67.00) 0.010
Percent of CD1c+CD192CD142CD3032 cells — — 23.471 0.03 (0.01–0.59) 0.021
N of CD3+CD16+CD56+ cells — — 20.020 0.98 (0.96–0.99) 0.021
OR, odds ratio.
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G7 TOSOH, Bioscience, Tokyo, Japan). Islet autoantibodies (GADA, IA-2A,
and IAA) were measured by commercial ELISA (Pantec, Torino, Italy).
Statistical analysis. Normally distributed continuous variables are reported
as mean 6 SD, median (min–max) was used to describe not-normally dis-
tributed continuous variables, and categorical variables are reported as
number of occurrences and percentages. For all study variables, comparison
among control subjects, high-risk subjects, and patients was based on the
nonparametric Kruskal-Wallis procedure, followed by the Mann-Whitney
U test with Bonferroni correction. Paired comparisons between patients at
baseline, after 12 months, and at 24 months from diagnosis were carried out
using the Friedman test, followed by Wilcoxon signed-rank test with Bonfer-
roni correction. The Spearman correlation coefficient was computed to in-
vestigate the biological correlations between the different variables.
Because of the large number of the variables examined and to control the
family-wise error rate at level a = 0.05, the significance of Kruskal-Wallis,
Friedman, and Spearman correlation P values were judged by using the
adaptive Bonferroni procedure (15,16).
A multivariable logistic regression model was fitted to predict the residual
C-pep secretion (dichotomized as 1 if#0.5 ng/mL and 0 if .0.5 ng/mL) after 12
months from the diagnosis on the basis of patients’ baseline measurements.
The following two-step model strategy was adopted. All variables reported in
Supplementary Tables 2 and 3 were tested in univariate analysis. Only the
variables that showed a univariate association with the outcome (P , 0.25)
were included in the subset of candidate predictors (17). Afterward, a back-
ward elimination procedure (with a probability for removal equal to 0.10) was
applied to identify those variables independently associated with the residual
C-pep. In this second step, the model was further adjusted for the following
covariates measured at diagnosis: age, BMI, and fasting C-pep secretion (di-
chotomized as 1 if #0.5 ng/mL and 0 if .0.5 ng/mL). This full model, including
variables independently associated with residual C-pep, was compared with
a base model including only the adjusting covariates of age, BMI, and C-pep
secretion measured at diagnosis. Prognostic validity of the fitted models was
evaluated by receiver operating characteristic (ROC) curve analysis and
measured using the area under the ROC curve (AUC). Comparisons among
different AUCs were carried out using the nonparametric approach (18). For
all analyses, we used two-sided tests, with P values , 0.05 denoting statistical
significance (unless otherwise specified). Modeling and statistical analyses
were carried out using R 2.12.1 and SPSS 16 (SPSS Inc., Chicago, IL) software.
RESULTS
Meta-immunological profiling of type 1 diabetic pa-
tients at onset, high-risk subjects, and control subjects.
To depict the immunological profile of type 1 diabetes at
onset, we analyzed several immune cell populations in the
FIG. 1. Meta-immunological profiling in patients at onset, in high-risk subjects, and in control subjects. Box plots show the distribution of cir-
culating level of leptin, sLepR, MCP-1, and sCD40 L in type 1 diabetic patients at onset, high-risk subjects, and control subjects. Dots represent
outlier values (i.e., data points below Q1 2 1.5 3 IQR or above Q3 + 1.5 3 IQR), and asterisks represent extreme values (i.e., data points below
Q1 – 3 3 IQR or above Q3 + 3 3 IQR). Q1 = 25th percentile; Q3 = 75th percentile; IQR (interquartile range) = Q3–Q1. Data are shown as median
(horizontal line in the box) and Q1 and Q3 (borders of the box). Whiskers represent the lowest and the highest values that are not outliers (i.e.,
data points below Q1 2 1.5 3 IQR or above Q3 1 1.5 3 IQR) or extreme values (i.e., data points below Q1 2 3 3 IQR or above Q3 1 3 3 IQR).
Patients had lower serum levels of Lep (P < 0.001) and higher serum levels of sLepR (P < 0.001) than control subjects. High-risk subjects had
intermediate levels of sLepR between children with type 1 diabetes and control subjects. Patients and control subjects had higher levels of MCP-1
than high-risk subjects; the same was observed for sCD40 L levels.
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peripheral blood of children at onset compared with high-
risk subjects and control subjects (Supplementary Table 2).
We found that patients at onset had a significantly lower
percentage of circulating CD8+ T cells compared with high-
risk subjects (P = 0.001, after Bonferroni correction) but not
compared with healthy control subjects. Furthermore, di-
abetic children also showed a significant higher number of
CD4+ T cells with a memory phenotype (CD4+CD45RO+)
compared with the control subjects (P = 0.03, after Bonfer-
roni correction). Finally, patients had a significantly higher
percentage (P = 0.03, after Bonferroni correction) and total
number (P = 0.01, after Bonferroni correction) of
CD303+CD1c2CD192CD142 pDCs compared with healthy
subjects (Supplementary Table 2).
To characterize the meta-immunological profile of type 1
diabetes, several indicators of inflammatory and metabolic
activities (leptin, sLepR, MCP-1, sCD40 L, MPO, sICAM-1,
resistin, OPG, and sTNFR) were analyzed (Fig. 1 and
Supplementary Table 3). Diabetic children at onset had
lower levels of Lep (P , 0.001, after Bonferroni correc-
tion) and higher concentrations of circulating sLepR than
high-risk (P , 0.001, after Bonferroni correction) and
control subjects (P , 0.001, after Bonferroni correction).
High-risk subjects showed intermediate levels of sLepR
between controls and patients (P , 0.001, after Bonferroni
correction; Fig. 1 and Supplementary Table 3). We also
observed that circulating levels of the proinflammatory
chemokine MCP-1 were significantly higher in children
affected by type 1 diabetes than in high-risk subjects (P ,
0.001, after Bonferroni correction) and significantly lower
in high-risk subjects than in controls (P , 0.001, after
Bonferroni correction). The same trend was observed for
FIG. 2. Immunological follow-up in type 1 diabetes. Children affected by type 1 diabetes were studied at diagnosis and at 12 and 24 months after disease
onset. Box plots show the distribution of CD4+ T cells, CD19+ B cells, CD4+CD45RO+ T cells, CD3+CD45RO+ T cells, CD3-CD16+CD56+ cells, and CD141+
cells and percentages of CD3+CD45RO+ T cells, CD3+CD16+CD56+ cells, and CD3+CD45RA+ T cells in patients at onset and after 12 and 24 months. Data
are shown as median (horizontal line in the box) and Q1 and Q3 (borders of the box). Whiskers represent the lowest and the highest values that are not
outliers (i.e., data points belowQ12 1.53 IQR or above Q31 1.53 IQR) or extreme values (i.e., data points belowQ12 33 IQR or above Q31 33 IQR).
Dots represent outlier values and asterisks represent extreme values. Q1 = 25th percentile; Q3 = 75th percentile; IQR (interquartile range) = Q3–Q1.
IMMUNOLOGICAL PROFILING AND TYPE 1 DIABETES
2484 DIABETES, VOL. 62, JULY 2013 diabetes.diabetesjournals.org
the circulating plasma levels of sCD40 L (Fig. 1 and Sup-
plementary Table 3).
Meta-immunological follow-up profiling of type 1
diabetes. Sera from patients were also analyzed at follow-
up, namely at 12 and 24 months after disease diagnosis.
During disease progression, a significant progressive re-
duction was found in the number of CD4+ T cells, with the
lowest values at 24 months after diagnosis (Fig. 2). The
same trend was observed for the absolute number of
circulating CD19+ B cells. In addition, during disease
progression, there was a progressive reduction in the
absolute number of circulating T cells with a memory
phenotype (CD4+CD45RO+ or CD3+CD45RO+). Con-
versely, the percentage of naïve T cells (CD3+CD45RA+)
was lower at disease onset compared with values ob-
served at later time points. In addition, there were higher
absolute numbers of natural killer (NK) cells (P = 0.002,
after Bonferroni correction) and CD141+CD1c2CD192
CD142CD3032 mDC2s at 12 months compared with those
observed at 24 months after disease onset (P = 0.006, after
Bonferroni correction). The CD3+CD16+CD56+ cells subset
was lower at onset than at later time points. In serum, a
progressive decline of circulating sLepR levels at 12 and at
24 months (P , 0.001 for both, after Bonferroni correc-
tion) and a progressive reduction of circulating OPG were
observed from disease onset thereafter (Fig. 3). Finally,
we also generated over-time analyses showing single
trajectories at the individual level for immunological and
metabolic parameters in type 1 diabetes patients (Supple-
mentary Figs. 1 and 2).
Multiple correlations among meta-immunological
markers. We performed multiple correlation analyses in
diabetic patients at onset, in high-risk individuals, and in
control subjects. In the group affected by type 1 diabetes,
sLepR inversely correlated with circulating levels of fast-
ing C-pep (r = 20.39, P , 0.001), which reflects b-cell
function. This correlation was not present in control sub-
jects or in high-risk subjects (Fig. 4 and data not shown).
Moreover, in patients at onset, the circulating levels of
resistin positively correlated with levels of sTNFR
(r = 0.47, P , 0.001), MCP-1 (0.52 with P , 0.001), and
MPO (r = 0.71, P , 0.001). Circulating MCP-1 positively
correlated with MPO (r = 0.62, P , 0.001) and sTNFR
levels (r = 0.52 with P, 0.001). All these correlations were
not present in control subjects and in high-risk subjects
(Fig. 4 and data not shown).
Several correlations in immune cell subsets were only
found in patients and not in control subjects and high-risk
subjects. In particular, only in the patients, the percentage
of CD3+ cells inversely correlated with the percentage of
NK (r = 20.41, P , 0.001) and B cells (r = 20.65, P ,
0.001). Moreover, the NK cells inversely correlated with
CD3+CD45RA+ (r = 20.51, P , 0.001) and CD4+CD45RA+
(r = 20.46, P , 0.001) naïve T cells (Fig. 4).
One-year follow-up. Meta-immunological correlations in
diabetic patients at onset and at 12 months after diag-
nosis were also studied. Significant differences were
observed compared with the same patients at diabetes
onset (Fig. 5). For example, the inverse correlation be-
tween sLepR and fasting C-pep observed at disease onset
was lost after 12 months. A series of positive correlations
at diagnosis, such as resistin versus MCP-1 (r = 0.52, P ,
0.001) and MPO (r = 0.70, P , 0.001) as well as MCP-1
versus MPO (r = 0.22, P , 0.01) were observed. Only
the correlation between resistin and MPO was main-
tained over time (r = 0.51, P , 0.001; Fig. 5). At the
cellular level, the correlations among the percentage of
CD3+ T cells versus NK and B cells observed at diagnosis
was lost after 12 months, whereas the percentage
CD4+CD45RO+ T cells inversely correlated with that of
CD3+CD45RA+ T cells and CD4+CD45RA+ T cells at dis-
ease onset. These correlations were not maintained 1
year later (Fig. 5).
Novel predictive tool of residual b-cell function over
time. The possibility to predict residual C-pep levels after
disease onset and the identification of biomark-
ers assessing therapeutic efficacy is a major goal in
type 1 diabetes monitoring and prognosis. Multivariable
logistic regression analysis showed that the number
of D3+CD16+CD56+ T cells and the percentage of
FIG. 3. Metabolic follow-up in type 1 diabetes. Box plots show the distribution of circulating levels of sLepR and OPG in diabetic children at onset
and 12 and 24 months later. Patients had very high circulating levels of sLepR at disease onset. Serum levels of sLepR showed a trend toward
reduction over time, with lower serum levels after 24 months from disease onset (P < 0.001). Serum levels of OPG progressively decreased over
time (P = 0.011). Data are shown as median (horizontal line in the box) and Q1 and Q3 (borders of the box). Whiskers represent the lowest and the
highest values that are not outliers (i.e., data points below Q12 1.53 IQR or above Q31 1.53 IQR) or extreme values (i.e., data points below Q12
3 3 IQR or above Q3 1 3 3 IQR). Dots represent outlier values and asterisks represent extreme values. Q1 = 25th percentile; Q3 = 75th percentile;
IQR (interquartile range) = Q3–Q1.
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FIG. 4. Multiple biological correlations in type 1 diabetes. Two-dimensional graphical representation of the Spearman r nonparametric correlation
matrix among the studied variables. The presence of a significant correlation between two variables is expressed by means of a red (negative
correlation) or blue (positive correlation) ellipse, and an empty circle refers to a nonsignificant correlation. The color intensity and thickness of
each ellipse are proportional to the correlation value (see graphic legend for numeric values). Correlation analysis, performed on all parameters
analyzed, revealed a distinctive immune/metabolic profile for controls and new-onset diabetic patients. A negative correlation between sLepR and
b-cell residual fasting C-pep secretion (r =20.39, P< 0.001) was observed in individuals affected by type 1 diabetes but not in controls. #Absolute
number of indicated cell populations with respect to the number of leukocytes; %percentage of indicated cell populations with respect to the
number of leukocytes.
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FIG. 5. Multiple biological correlations in type 1 diabetic children over time. Two-dimensional graphical representation of the Spearman r nonparametric
correlation matrix among the study variables. The presence of a significant correlation between two variables is expressed by means of a red (negative
correlation) or blue (positive correlation) ellipse, and an empty circle refers to a nonsignificant correlation. The color intensity and the thickness of each
ellipse are proportional to the correlation value (see graphic legend for numeric values). Correlation analysis, performed on all parameters analyzed,
revealed a distinctive immune/metabolic profile for children with type 1 diabetes over time. The inverse correlation between sLepR and fasting C-pep,
M. GALGANI AND ASSOCIATES
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CD1c+CD192CD142CD3032 mDC1s at disease diagnosis
were independent predictors of low (#0.5 ng/mL) residual
C-pep secretion after 12 months from diagnosis, after
adjustment for age and BMI as covariates measured at
diagnosis. The data in Table 1 report the regression co-
efficient and the corresponding odds ratio (95% CI) for the
model and for a reduced base model including only the
adjusting factors. In addition, a linear regression model
confirmed the predictive role of CD3+CD16+CD56+ T cells
and CD1c+CD192CD142CD3032 mDC1s independently of
age, BMI, and C-pep values at onset. The results of this
model are reported in Supplementary Table 4. Figure 6
shows the ROC curves associated to the base model and to
the full model. The AUC of the full model was 0.936 (P ,
0.001), and compared with the AUC of the base model
(0.781, P, 0.001), was significantly higher (P = 0.005). Box
plots in Fig. 6 indicate that low CD3+CD16+CD56+ T cells
and low mDC1s at disease onset associated with a reduced
b-cell activity (fasting C-pep #0.5 ng/dL) in type 1 diabetes
1 year later.
To characterize further the patients with different re-
sidual b-cell function, we performed a correlation analysis
of severe-disease patients (fasting C-pep #0.5 ng/dL) and
mild-disease patients (fasting C-pep .0.5 ng/dL) at disease
onset and 1 year later. We observed that in patients with
a worse pancreatic function (fasting C-pep #0.5 ng/dL),
resistin positively correlated with the levels of C-pep, MCP-1,
and sTNFR. In addition, there was also a positive corre-
lation in this group between MCP-1 and TNFR. These
correlations were not observed in patients with residual
b-cell function (fasting C-pep .0.5 ng/dL). An inverse
correlation between the percentage of naïve T cells
(CD4+CD45RA+) and memory T cells (CD4+CD45RO+) was
observed in severe-disease patients but not in mild-disease
patients. Many of the correlations observed at diabetes
onset were not present 12 months after disease onset. CD3+
positively correlated with CD4+ (and CD4+CD28+) in se-
vere-disease patients but not in mild-disease patients. Only
in mild-disease patients did we observe an inverse correla-
tion between CD3+CD45RA+ and CD3+CD45RO+ (Fig. 7).
observed at disease onset, was lost 12 months later. #Absolute number of indicated cell populations with respect to the number of leukocytes;
%percentage of indicated cell populations with respect to the number of leukocytes.
FIG. 6. Prediction analysis. A: ROC curves of the model-based prognostic scores for residual b-cell functioning. The base model included age, BMI,
and fasting C-pep secretion measured at disease onset, whereas the full model added the number of CD3+CD16+CD56+ T cells and the percentages
of mDCs to the base model. B: Box plot shows that high numbers of CD3+CD16+CD56+ T cells at onset are associated with a reduced b-cell activity
1 year later. Low numbers were associated with a residual b-cell function. C: Box plot shows that the high percentage of mDCs at onset was
associated with a reduced b-cell activity 1 year later. Conversely, low numbers of these cells were associated with residual b-cell function. Data are
shown as median (horizontal line in the box) and Q1 and Q3 (borders of the box). Whiskers represent the lowest and the highest values that are
not outliers (i.e., data points below Q12 1.5 x IQR or above Q31 1.53 IQR) or extreme values (i.e., data points below Q12 33 IQR or above Q31
3 3 IQR). Dots represent outlier values and asterisks represent extreme values. Q1 = 25th percentile; Q3 = 75th percentile; IQR (interquartile
range) = Q3–Q1. #Absolute number of indicated cell populations with respect to the number of leukocytes; %percentage of indicated cell pop-
ulations with respect to the number of leukocytes.
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FIG. 7. Distinctive correlation profiles of patients affected by type 1 diabetes according to disease severity at onset and 12 months later.
Graphical representation of the Spearman r nonparametric correlation matrix among the study variables. The presence of a significant cor-
relation between two variables is expressed by means of a red (negative correlation) or blue (positive correlation) ellipse, whereas an empty
circle refers to a nonsignificant correlation. The color intensity and thickness of each ellipse are proportional to the correlation value (see
graphic legend for numeric values). The correlation profile between patients with mild and severe disease at onset and 12 months later is
shown.
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DISCUSSION
The comprehension of the pathogenesis of type 1 diabetes
has improved considerably in recent years, yet there is
a lack of predictive markers of risk for disease progression
and pancreatic b-cell loss. Such markers could be very
useful to monitor the disease, to ameliorate prognosis, and
to evaluate therapeutic efficacy.
The meta-immunological profiling described here for
type 1 diabetes at onset and during progression identified
three circulating immune cell populations and four meta-
bolic/inflammatory markers as significantly different
among diabetic patients at onset, in high-risk subjects, and
in control subjects. CD8+ T lymphocytes were significantly
higher in high-risk subjects than in patients in accordance
with a previous report (19), a finding that is reminiscent of
the known increased proliferation of this cell subset during
insulitis, before the onset of hyperglycemia and overt di-
abetes. Higher numbers of memory T cells in patients at
onset than in controls were also found. Interestingly, in the
24-month follow-up, there was a progressive decline in the
number of memory T cells in diabetic patients, in accor-
dance with the findings that GAD65-specific T cells in di-
abetic patients bear a memory phenotype, whereas they
are naïve T cells in healthy individuals (20). We hypothe-
size that the progressive decrease of memory T cells might
be secondary to a gradual exhaustion of islet-specific
T-cell clones after initial epitope spreading. Moreover,
pDCs were higher in children with type 1 diabetes at onset
compared with healthy children. This aspect is interesting,
because in the presence of b-cell–specific autoantibodies,
pDCs process and present islet autoantigens to CD4 T cells
to amplify and maintain T-cell responses favoring epitope
spreading (21). Previous investigations studied the fre-
quency of this cell subset with discrepant results, showing
a reduced pDCs number in the blood of patients compared
with healthy controls (10,22,23) or an increased frequency
of pDCs at diagnosis of type 1 diabetes (24). These con-
flicting results could depend on the procedures for the
analysis, the timing of sampling, and the size of the studied
population. Our study is the first to analyze pDCs longi-
tudinally for 24 months in a large cohort of patients after
disease diagnosis.
Metabolically, the leptin/sLepR axis was altered in newly
diagnosed diabetic children compared with high-risk sub-
jects and control subjects. Leptin profoundly affects me-
tabolism and immune functions (25) and promotes the
development of type 1 diabetes in NOD mice (26,27). On
the contrary, it has been reported that leptin improves
insulin-deficient type 1 diabetes, reverting catabolism
through the suppression of hyperglucagonemia, resembling
the anabolic action of insulin monotherapy, and normalizing
HbA1c (27). sLepR, the main leptin-binding protein in hu-
man blood, can modulate leptin effects on target organs by
influencing leptin action in two ways: 1) by inhibiting the
binding of leptin to its membrane receptors, and 2) by in-
creasing the availability of Lep, thus delaying its clearance.
We found that children affected by type 1 diabetes at di-
agnosis had lower Lep and higher sLepR levels compared
with high-risk and control subjects, which is consistent with
the report of elevated serum sLepR in diabetic children with
metabolic decompensation (28). Low levels of leptin in
subjects with type 1 diabetes could be partially explained by
the high amount of sLepR in the same patients. sLepR could
mask leptin epitopes and hamper detection of this adipo-
kine. The behavior of sLepR levels during diabetes
progression suggests a potential of sLepR as an early novel
marker of type 1 diabetes. This is linked to the finding that
sLepR levels decreased over time during diabetes pro-
gression but still remained higher than in healthy control
subjects. In addition, sLepR circulating levels inversely
correlated with b-cell function, measured as levels of cir-
culating fasting C-pep, at disease onset (Fig. 4). This
finding was not confirmed in high-risk and control groups,
although the lack of significance could be attributed to the
reduced power due to smaller sample size for those
groups. A better understanding of the mechanisms con-
trolling the leptin/sLepR axis may lead to speculation on
the possibility of using leptin as a substitute for or a com-
bination therapy with insulin in type 1 diabetes.
The importance of our study relies on the current lack of
markers able to predict diabetes progression and severity
in type 1 diabetes. Such markers could help clinicians in
choosing the most appropriate therapeutic intervention, in
disease monitoring, and in the evaluation of therapeutic
efficacy, ultimately improving prognosis. Because type 1 di-
abetes is a complex multifactor disease with a strong ge-
netic component and significant environmental influences, a
broad immunological assessment and multifactor algorithm
to pick patterns is likely needed to dissect the complex
pathogenesis and identify key patterns of disease progres-
sion. By using a multivariate logistic regression analysis
adjusted for age, BMI, and the value of fasting C-pep at dis-
ease onset, we identified here two specific immune cell
populations, both measured at disease onset, that were
capable to predict C-pep secretion as a surrogate measure
of b-cell mass in humans with type 1 diabetes (29). Indeed,
the number of CD3+CD16+CD56+ T cells and the percentage
of mDC1s were independent predictors of residual C-pep
secretion 12 months after diagnosis.
Our prognostic score of the fitted model reached an
AUC that was significantly higher than the AUC of a prog-
nostic base model that included only age, BMI, and fasting
C-pep measured at disease onset (P , 0.001). We also
provided a wide range of biological correlates of disease
compared with healthy and disease-progressing individuals.
The biological correlations between meta-immunological
parameters in subjects with mild and severe type 1 diabetes
indicated that in mild-disease patients, the T cells nega-
tively correlated with NK and B cells, both correlations
not detectable in subjects with severe disease. An advan-
tage of the current study is the multiparametric analysis
on a large, well-characterized cohort of newly diagnosed
patients with type 1 diabetes monitored prospectively and
longitudinally for 24 months. As such, this is the first com-
prehensive study associating b-cell secretion capability with
circulating immune cell subsets. The number and percent-
age of mDC1s and CD3+CD16+CD56+ T cells were prog-
nostic factors of pancreatic insulin secretion up to 1 year
after disease onset. Finally, our approach could also be of
valuable help to understand the molecular basis of slow
versus fast progressors to disease and to monitor high-risk
subjects toward the development of b-cell failure in con-
junction with tests measuring the acute insulin response to
glucose (i.e., AIR-glucose), which could reflect very early an
ongoing immune attack against insulin producing b-cells.
In conclusion, our experimental model could represent
a novel tool to monitor the staging of type 1 diabetes
patients and may be useful, together with previously
known parameters (i.e., HbA1c, insulin requirement), to
assess disease progression and also contribute to define
the most appropriate therapeutic approach according with
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the aggressiveness of the disease at onset. Our results
could lead to the discovery and/or validation of bio-
markers that represent early events in the disease as well
as those that may serve as surrogate read-outs or end
points for efficacy of specific interventions.
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